Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
2201-2220 of 2,251 trials

Cemiplimab and Imiquimod for High-Risk Basal Cell Carcinoma

We are studying a combination of cemiplimab, imiquimod, and laser therapy for patients with high-risk cutaneous basal cell carcinoma. The goal is to evaluate safety and how well this treatment works before surgery.

Skin Cancer (Basal Cell Carcinoma)>2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesDermatologyOncology

Advanced Colorectal Cancer: OMTX705 Combination Therapy

We are studying a new drug, OMTX705, combined with regorafenib and tislelizumab for patients with advanced colorectal cancer. The goal is to evaluate its safety and effectiveness in those who have not responded to previous treatments.

Metastatic Colorectal Cancer1-2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Fluid Management in Critically Ill Adults: CRUSADERS Trial

We are studying whether reducing sodium and chloride in fluids helps critically ill adults have better health outcomes. This includes looking at effects on organ support needs and overall survival.

Healthy Participants>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInternal MedicineNephrology

Inflammatory Rheumatic Diseases: JAK Inhibitor Dose Reduction Study

We are exploring if lowering the dose of JAK inhibitors is as effective as keeping the current dose for patients with rheumatoid arthritis, psoriatic arthritis, or axial spondyloarthritis in low disease activity. This study will also look at safety and how many patients can successfully reduce their medication.

Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis1-2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteInternal MedicineRheumatology

Tonsillectomy Pain Relief: Ropivacaine vs. Lidocaine

We are comparing two local anesthetics to see which one better reduces pain after tonsillectomy. This study aims to find the most effective option for managing postoperative discomfort.

Chronic Tonsillitis6-12 monthsMonitoring phase (IV)No PlaceboStandard MedicinesOtolaryngology

Postoperative Pain Relief: High Dose Dexamethasone for Lung Surgery

We are studying whether a higher dose of Dexamethasone can reduce pain after video-assisted thoracoscopic surgery in patients who typically experience high pain. This trial compares a high dose to a standard lower dose to find the best pain management approach.

Lung Cancer≤3 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesInternal MedicineOrthopedics and TraumatologyOtolaryngologyPulmonology

Choline Alfoscerate for Elderly with Subthreshold Depression

We are studying whether choline alfoscerate can help improve symptoms of subthreshold depression in elderly patients. The trial also looks at its effects on cognitive symptoms and apathy.

Under Threshold Depression in the Elderly1-2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesPsychiatry

Etrasimod in Breastfeeding Women

We are studying how the medication etrasimod is absorbed into the blood and breast milk of healthy lactating women. This research will help us understand its safety and potential effects on breastfeeding infants.

Ulcerative Colitis1-2 yearsSafety phase (I)No PlaceboStandard MedicinesGastroenterologyGynecology and Obstetrics

Congenital Pseudarthrosis of the Tibia: NVD003 Treatment Study

We are evaluating how effective and safe NVD003 is for children undergoing surgery for congenital pseudarthrosis of the tibia. The study will also look at its impact on bone healing and quality of life.

Congenital Pseudarthrosis>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOrthopedics and TraumatologyPediatrics

Graves' Disease: Rilzabrutinib Study

We are investigating whether rilzabrutinib can help reduce thyroid activity in adults with Graves' disease. The study also aims to evaluate the safety of this new treatment.

Graves' Disease3-6 monthsEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesPartially RemoteEndocrinologyInternal Medicine

Pomalidomide for Chronic Hepatitis B Infection

We are studying the safety of pomalidomide in people with chronic hepatitis B. The trial also looks at how this medication may improve immune responses and liver health.

Hepatitis B Virus Infection6-12 monthsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesHepatologyInfectious Diseases

Parkinson's Disease: Lecigon® Therapy

We are studying a new treatment combining levodopa and entacapone for people with Parkinson's disease. The goal is to see if it helps reduce certain symptoms and improve overall well-being compared to standard treatments.

Parkinson's Disease>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesNeurologyPsychiatry

Darolutamide and Bipolar Androgen Therapy for Advanced Prostate Cancer

We are studying whether combining Darolutamide with bipolar androgen therapy improves survival and quality of life for men with metastatic castration-resistant prostate cancer compared to standard treatments.

Metastatic Castration-Resistant Prostate Cancer>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncologyUrology

Zelenectide Pevedotin for Advanced Non-small Cell Lung Cancer

We are studying a new treatment for patients with advanced or metastatic non-small cell lung cancer that has NECTIN4 amplification. The goal is to see how well it works and how safe it is for those who have already been treated.

Advanced Non-small Cell Lung Cancer1-2 yearsEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesOncology

Multiple Sclerosis: Subcutaneous vs. Intravenous Ublituximab

We are studying how a new subcutaneous injection of ublituximab compares to the intravenous version for people with relapsing multiple sclerosis. The goal is to evaluate its safety and effectiveness in managing the condition.

Relapsing Multiple SclerosisConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementNeurology

Non-Small Cell Lung Cancer: RMC-9805 and RMC-6236 Study

We are studying a new treatment combination for patients with RAS G12D-mutant non-small cell lung cancer. The trial will evaluate the safety and effectiveness of these drugs alongside other anticancer therapies.

Non-small Cell Lung Cancer3-6 monthsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncologyPulmonology

Mantle Cell Lymphoma: Acalabrutinib with R-CHOP

We are studying the combination of acalabrutinib and R-CHOP for patients with previously untreated mantle cell lymphoma. The goal is to see if this combination improves treatment response and is safe.

Mantle Cell Lymphoma>2 yearsEfficacy phase (II)16-20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology

Chronic Subdural Hematoma: Timing of Anticoagulation

We are studying whether starting blood-thinning medication early or later helps patients with atrial fibrillation recover better after surgery for chronic subdural hematoma. This research looks at potential risks and overall health outcomes.

Chronic Subdural HematomaAtrial Fibrillation3-6 monthsEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesPartially RemoteCardiologyInternal MedicineNeurology

Immunotherapy for Metastatic Colorectal and Prostate Cancer

We are studying a new treatment using patients' own immune cells to see if it is safe and tolerable for those with advanced colorectal or prostate cancer. The trial will help us understand how well this therapy works in these patients.

Locally Advanced or Metastatic Prostate CancerMetastatic Colorectal Cancer>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesPartially RemoteGastroenterologyOncologyUrology

Birth Control Study: Levonorgestrel Tablet

We are investigating whether the Levonorgestrel tablet can still prevent ovulation despite planned delays in taking the pill. This study is for individuals interested in understanding the reliability of this contraceptive method.

Ovulation Inhibition6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesGynecology and Obstetrics